Cellectis and Pfizer enter into global strategic collaboration to develop immunotherapies - CAR-T
Pfizer Inc. (NYSE: PFE) today announced they have and Cellectis (ALCLS Paris) entered into a global strategic collaboration to develop chimeric T-cell Antigen Receptor (CAR-T) immunotherapy in oncology directed to selected targets. CAR-T Cellectis technology platform provides a unique approach, allogeneic (using T cells changed from a single donor for use in several patients) for the development of therapies that CAR-T differs from other approaches autologous (engineering own T-lymphocytes of a patient to target tumor cells).
under the terms of the agreement, Pfizer has exclusive rights for further development and commercialization of therapies CAR-T, in the field of oncology, for a total of five objectives set by Pfizer . The two companies will work together on the preclinical and Pfizer will be responsible for the development and eventual commercialization of CAR-T therapy for Pfizer-selected targets. In addition, the agreement provides for a total of twelve targets selected by Cellectis. The two companies will work together on preclinical research on four selected and Cellectis Cellectis targets work independently on eight additional targets. Cellectis will be responsible for clinical development and commercialization of therapeutic CAR-T for the selected targets Cellectis. Pfizer has the right of first refusal for the four selected Cellectis targets.
Cellectis will receive an upfront payment of $ 80 million, and the financing costs of research and development associated with Pfizer-selected goals and four Cellectis- selected targets within the collaboration. Cellectis is eligible to receive development, payment of regulatory and commercial milestones up to $ 185 million by Pfizer product. Cellectis is also eligible to receive tiered royalties on net sales of any products that are marketed by Pfizer.
In addition, Pfizer will enter into an agreement on equity to purchase approximately 10% of the capital of Cellectis by newly issued shares at 9.25 Euro per share, pending approval shareholders of Cellectis. Approval by two-thirds of the votes cast by shareholders voting Cellectis is necessary for transmission. Cellectis shareholders representing 52.8% of the voting rights have already undertaken to vote in favor of the issue. In the case of the sale of shares are not approved by the shareholders of Cellectis, Pfizer has the option to terminate the collaboration agreement.
Cellectis plans to open a site in the United States to work more closely with Pfizer scientists.
"We believe our technology platform CAR-T has the potential to offer a real advantage over other receptor T cell engineering approaches and collaboration with Pfizer is an important step towards the full potential of this technology to harness the immune system of the body to fight against cancer, "said André Choulika, PhD, President and CEO of Cellectis." this alliance provides access to state art-therapeutic development of Pfizer's capabilities and provides a unique opportunity to advance this innovative work to develop the best in its therapeutic class CAR-T. We look forward to working closely with the Pfizer team research and development of new CAR-T therapy that could change the way cancer is treated. "
" This immuno-oncology collaborative leader to provide immunotherapies is built on advanced genome editing and Cellectis cell engineering capability and advanced biotherapeutics cancer treatment platform of Pfizer, "said Mikael Dolsten, MD, PhD, President of R & D at Pfizer. "The combination of innovation and scientific expertise of Cellectis with experience in oncology and immunology deep Pfizer creates a world class partnership designed to offer a new generation of CAR-T immunotherapy for cancer patients with needs urgent medical. "
EmoticonEmoticon